Mogrify Limited

[Available On-Demand]
Mogrify’s mission is to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies. Using its proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular conversion (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems, 2020). The platforms, MOGRIFY® and EpiMOGRIFY, developed over a 12-year period via a multi-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors (or small molecules) and optimal culture conditions required to produce any target human cell type from any source human cell type.

Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
Immunology/Ophthalmology
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Corporate Development Officer
Mogrify Limited